MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    Handwriting Features in Patients with Isolated REM Sleep Behaviour Disorder

    R. Torricelli, J. Kenny, E. Bache, L. Pérez-Carbonell, B. Huxford, H. Chohan, G. Leschziner, A. Lees, A. Schrag, A. Noyce, C. Simonet (London, United Kingdom)

    Objective: To assess iRBD patients’ handwriting features and develop a rating scale capable of detecting early hallmarks of disease. Background: Handwriting changes, such as micrographia,…
  • 2024 International Congress

    Slc2a13, a risk gene for Parkinson’s disease associated with Snca and Lrrk2

    JW. Li, GX. Zhang, T. Wang, ZC. Lin, N. Xiong (Wuhan, China)

    Objective: To exploit the potential function of the risk gene Slc2a13 in PD progression. Background: 越来越多的证据证实了总体遗传位点和候选基因对帕金森病的贡献,以及两个最确定的风险基因,即α-突触核蛋白(Snca)和富含亮氨酸的重复激酶2(Lrrk2)。Slc2a13 编码哺乳动物肌醇转运蛋白,被认为是一种群体依赖性风险基因。越来越多的证据支持这样一种观点,即 Slc2a13 活性的改变强调了 PD 的发展。剖析转运蛋白活性降低如何导致多巴胺能神经元变性和丧失,可能会进一步加深我们对功能的理解。 Method: A total of 338 cases…
  • 2024 International Congress

    Distinct patterns of Gene Expression in Skin-biopsy Derived Fibroblasts of Patients with Parkinson’s disease

    T. Ntetsika, I. Markaki, A. Damdimopoulos, M. Zeitelhofer, P. Tsitsi, M. Zeitelhofer Adzemovic, P. Svenningsson (Stockholm, Sweden)

    Objective: In this study, we aimed to investigate global gene expression alterations in cultured skin fibroblasts from individuals with idiopathic Parkinson’s disease (PD) compared to…
  • 2024 International Congress

    Comorbidities in genetic Parkinson’s Disease: comparison between LRRK2, GBA1, and non-mutated PD

    G. Di Rauso, F. Pirone, G. Franco, F. Arienti, I. Trezzi, E. Frattini, F. Cavallieri, V. Rispoli, F. Valzania, E. Monfrini, A. Di Fonzo (Reggio Emilia, Italy)

    Objective: To examine the occurrence of medical comorbidities associated with genetic form of Parkinson’s disease (GBA1-PD and LRRK2-PD) compared to a cohort of non-mutated PD…
  • 2024 International Congress

    Expanding Diversity of Parkinson’s Disease and Related Disorders Genetic Data: from the Global Parkinson’s Genetics Program

    G. Parkinson'S_genetics_program (gp2) (Bethesda, USA)

    Objective: To expand the research dataset for Parkinson’s Disease (PD) and related disorders by including >50,000 participants globally who have been genotyped or whole genome…
  • 2024 International Congress

    LRRK2 Gene Mutation in Parkinson’s Disease

    A. Abbes, M. Mhiri, R. Ben Dhia, N. Gouta, M. Frih Ayed (Monastir, Tunisia)

    Objective: We aim to describe the clinical characteristics of PD linked to an LRRK2 mutation. Background: One of the most common monogenic forms of Parkinson's…
  • 2024 International Congress

    Correlation of Neural Sensing with the Volume of Neural Activation within the Desired Patient-Specific Anatomical Target in Deep Brain Stimulation for Parkinson’s Disease

    M. Case, C. Zarns, A. Holt-Becker, R. Raike, E. Radcliffe, J. Thompson, D. Kern (Minneapolis, USA)

    Objective: Investigate the correlation between power in local field potential (LFP) beta band sensed from the subthalamic nucleus (STN) and the volume of neural activation…
  • 2024 International Congress

    Exploring the Therapeutic Potential of Microglial Modulation in Parkinson’s Disease: A Study on Structural Synaptic Plasticity

    F. Fares Taie, I. Taravini, L. Rela (Buenos Aires, Argentina)

    Objective: We aim to explore the role of glial cells in Parkinson's disease and assess whether modulating microgliafunction could offer therapeutic benefits. Specifically, we investigate…
  • 2024 International Congress

    A pathology-validated study to investigate the role of Uric Acid in Parkinson’s Disease

    P. Pecoraro, S. Carbone, V. Di Lazzaro, L. Di Biase (Rome, Italy)

    Objective: The aim of this study is to compare plasma uric acid levels between pathology-confirmed and clinically misdiagnosed Parkinson’s disease patients at a single-patient level.…
  • 2024 International Congress

    Burden of Movements Disorders at Initiative Plus Center Hospital

    P. Kiatoko, K. Luse (KINSHASA, The Democratic Republic of the Congo)

    Objective: describe the socio-demographic, clinical characteristics and evolutionary profiles of patients followed for movement disorders Background: The DR Congo specialists in abnormal movements are rare,…
  • « Previous Page
  • 1
  • …
  • 166
  • 167
  • 168
  • 169
  • 170
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley